July 22, 2025
StemRIM Inc.

StemRIM Announces Progress of the Additional Phase 2 Clinical Trial on Redasemtide (HMGB1 Fragment Peptide) for Dystrophic Epidermolysis Bullosa

Osaka, Japan, July 22, 2025 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that patient enrollment for the additional phase 2 clinical trial on Redasemtide, which was previously out-licensed from our company to Shionogi & Co., Ltd (TSE:4507, Representative Director, President and CEO: Isao Teshirogi ; "Shionogi"), for dystrophic epidermolysis bullosa has been completed.

This clinical trial targets patients with dystrophic epidermolysis bullosa accompanied by refractory ulcers and aims to investigate the efficacy of Redasemtide against refractory ulcers. As an efficacy evaluation measure, the presence or absence of ulcer closure within 52 weeks from the start of administration of the investigational drug is being assessed.

It should be noted that Redasemtide was designated as an orphan drug for dystrophic epidermolysis bullosa by the Ministry of Health, Labour and Welfare in May 2023, and early approval is expected through the application of the priority review system.

For an overview of this clinical trial, please refer to the Japan Registry of Clinical Trials (commonly known as jRCT), a clinical research database (Clinical Trial Plan and Study Summary Disclosure System).

(Reference) https://jrct.mhlw.go.jp/latest-detail/jRCT2031220378

At this time, there is no impact on the financial results for the fiscal year ending July 31, 2025, due to this matter. However, we believe it will contribute to the enhancement of our corporate value over the medium to long term.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing

the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
X: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)